Vote in the European Parliament

Laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795

Tomislav Sokol – After recital 12 – Am 256
Date: 20.01.2026·Reference: A10-0272/2025
Rapporteur: Tomislav Sokol

Overall Result

Adopted
  • 362 For
  • 259 Against
  • 34 Abstention
  • 64 Did not vote
Amendment— You are viewing a sub-vote (amendment) of the main vote.Amendment 256 · Draft legislative act · Tabled by RenewView amendment at the EP ↗
Amendment wording

Tabled by Vlad Vasile-Voiculescu

Added: (12 a) Contraceptives and abortifacient medicinal products are essential in safeguarding sexual and reproductive health rights, gender equality and the full enjoyment of fundamental rights everywhere in the Union. Shortages and supply disruptions affecting these medicinal products of common interest undermine patient safety and contribute to unequal access to healthcare across the Union. In order to safeguard sexual and reproductive health rights and equal access to contraceptive and abortifacient medicinal products for all women in the Union, Member States should ensure availability, affordability and security of supply of these medicinal products of common interest.

Wording as published by the EP, in English. PE781.998

← Back to Main Vote
Status and procedure

Outcome as recorded by the European Parliament.

Vote held on
Latest recorded step
Committee stage · (122 days ago)
Next scheduled step
Plenary · (in 12 days)

Procedure timeline

2025/0102(COD) · COD

Recorded procedure activities. These do not establish whether a law has entered into force.

  1. Recorded: Referral58 days until the next step
  2. Recorded: Committee stage154 days until the next step
  3. Recorded: Plenary32 days until the next step
  4. Recorded: Negotiations175 days until the next step
  5. Latest recorded: Committee stage122 days since this step began
  6. Planned: Plenary
Recorded activities (25)
  1. Referral to committee
  2. Committee report tabled
  3. Committee amendments tabled
  4. Committee amendments tabled
  5. Committee amendments tabled
  6. Committee opinion adopted
  7. Committee opinion adopted
  8. Committee opinion adopted
  9. Committee report adopted
  10. Tabling for plenary
  11. Tabling for plenary
  12. Tabling for plenary
  13. Tabling for plenary
  14. Tabling for plenary
  15. Tabling for plenary
  16. Tabling for plenary
  17. Plenary debate
  18. Text amended in plenary
  19. Referred back to committee for interinstitutional negotiations
  20. Plenary vote
  21. Plenary vote results
  22. Interinstitutional negotiations
  23. Interinstitutional negotiations
  24. Interinstitutional negotiations
  25. Provisional agreement approved in committee
Scheduled activities (not confirmation of completion)
  1. Plenary debate
  2. Plenary vote
  3. Plenary vote

Procedure file (OEIL) · European Parliament data
Retrieved:

Sources

Data: EP Open Data API

What is this about?

  • This regulation seeks to enhance the security of supply and availability of critical medicines across the EU.
  • It establishes a framework to diversify supply chains and incentivize investments in local manufacturing capacities.
  • Special focus is placed on older, off-patent drugs through targeted financial support and streamlined approval processes.
  • Coordination among member states aims to reduce market fragmentation and strengthen the internal market.
  • The goal is to bolster the EU’s strategic autonomy in the healthcare sector.
Source: Explanatory Statement (AI Generated)

Vote by political group

How the political groups voted

Members

Showing 10 of 719

Vote Position
NameCountryGroupVote Position
SpainS&D
For
GermanyGreens/EFA
For
GermanyGreens/EFA
For
CyprusGUE/NGL
For
GermanyGreens/EFA
For
NetherlandsS&D
For
RomaniaS&D
For
RomaniaEPP
For
EstoniaRenew
For
CzechiaGreens/EFA
For
Show more
Follow us on Instagram@checksomevotes@checksomevotes_en